Eris Lifesciences posts analyst call transcript for Q4FY26

Eris Lifesciences Limited has informed the stock exchanges that the transcript of its Analyst and Investor call is now available. The call was held following the announcement of financial results for the quarter and year ended March 31, 2026. This disclosure allows stakeholders to access a detailed record of management's commentary on the company's performance for the period.

The communication was submitted to BSE Limited and National Stock Exchange of India Limited. The transcript provides a comprehensive review of the audited consolidated and standalone financial results discussed during the proceedings.

Conference Call Details

The session covered the financial performance of the company for the specified period. Investors and interested parties can review the management's analysis by accessing the document online.

Event	Details
Subject	Transcript of Analyst and Investor call for Q4 and FY ended March 31, 2026
Availability	Available on company website

Access Information

The transcript can be accessed via the following link on the company's website: https://eris.co.in/financials/ . The specific file name for the document is "Transcript of the Analyst and Investor Conference call Q4FY26".

The communication was signed by Milind Talegaonkar, Company Secretary and Compliance Officer of eris lifesciences .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.50%	+3.39%	+8.57%	-5.57%	-9.05%	+108.44%

Eris Lifesciences Limited has announced that its management will participate in an investor conference with Franklin Templeton. The meeting is scheduled to take place virtually on Friday, May 29, 2026.

The interaction will be led by Mr. Krishnakumar Vaidyanathan, a management representative from the company. The session is set to begin at 10:30 AM IST and will be conducted in a one-on-one format.

Meeting Details

The following table outlines the specifics of the scheduled interaction:

Day and Date	Fund Name	Management Representatives	Mode of Meeting	Meeting Details
Friday, May 29, 2026	Franklin Templeton	Mr. Krishnakumar Vaidyanathan	Virtual	10:30 AM IST, 1X1

The company has clarified that the schedule provided is indicative and subject to change due to unforeseen developments. During the meeting, the management will refer to publicly available documents for discussions.

Eris Lifesciences Limited emphasized that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.